1. Fang, Deliang, Ou, Xinde, Sun, Kaiyu, Peng, Jianjun, Xu, Jianbo. 2022. m6A modification-mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability. In Cancer science, 113, 4135-4150. doi:10.1111/cas.15581. https://pubmed.ncbi.nlm.nih.gov/36114757/
2. De, Pradip, Carlson, Jennifer H, Leyland-Jones, Brian, Dey, Nandini. 2015. Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work? In American journal of cancer research, 5, 2872-91. doi:. https://pubmed.ncbi.nlm.nih.gov/26609493/
3. Li, Yuchun, Wang, Kaijuan, Dai, Liping, Ye, Hua, Zhang, Jianying. 2012. HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility. In Oncology letters, 4, 358-364. doi:. https://pubmed.ncbi.nlm.nih.gov/22844383/
4. Ventelä, Sami, Sittig, Eleonora, Mannermaa, Leni, Grénman, Reidar, Westermarck, Jukka. . CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. In Oncotarget, 6, 144-58. doi:. https://pubmed.ncbi.nlm.nih.gov/25474139/
5. Tarek, Mohammad M, Yahia, Ahmed, El-Nakib, Mostafa M, Elhefnawi, Mahmoud. 2021. Integrative assessment of CIP2A overexpression and mutational effects in human malignancies identifies possible deleterious variants. In Computers in biology and medicine, 139, 104986. doi:10.1016/j.compbiomed.2021.104986. https://pubmed.ncbi.nlm.nih.gov/34739970/
6. Hasanin, Reem, Mossallam, Ghada, Elfishawi, Sally, Rabea, Ahmed, Hamdy, Nayera. 2022. Overexpression of cancerous inhibitor ofPP2A (CIP2A) in acute myeloid leukemia. In Expert review of hematology, 15, 465-471. doi:10.1080/17474086.2022.2072825. https://pubmed.ncbi.nlm.nih.gov/35502616/
智鼠故事 
